Mogamulizumab Q4week Dosing in Participants With R/R CTCL

Trial ID or NCT#

NCT04745234

Status

not recruiting iconNOT RECRUITING

Purpose

This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening Period during which participants are screened for entry into this study, followed by a treatment period of up to 2 years from Cycle 1 Day 1.

Official Title

Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants With Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * Histologically confirmed diagnosis of MF or SS
  2. * Stage IB, II-A, II-B, III, or IV;* Participants who have failed at least one prior course of systemic therapy (e.g., interferon, bexarotene, photopheresis, anti-neoplastic chemotherapy). Psoralen plus ultraviolet light therapy (PUVA) is not considered a systemic therapy.
Exclusion Criteria:
  1. * Current evidence of large cell transformation;* Prior treatment with mogamulizumab;* History of allogeneic transplant.
View All Criteria
Show Less

Contact us to find out if this trial is right for you.

Contact

Kumari Khushboo

View on ClinicalTrials.gov